Endosense (www.endosense.com) was founded in 2003 in Geneva. It is a medical technology company focused on improving the efficacy, safety and accessibility of catheder ablation for the treatment of cardiac arrhythmias. The company pioneered the use of Contact Force measurement in catheter ablation with the development of TactiCath®, the industry’s first force-sensing ablation catheder.
Gimv is shareholder of Endosense since the series B round in 2009, in which the company received over CHF 38 million from Gimv, Edmond de Rothschild Investment Partners, Neomed, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie and NGN Capital. In 2005, the enterprise already received CHF 22.6 million in its first financing round.
Based on the upfront payment, the sale already has a positive impact of EUR 5.4 million (EUR 0.22 per share) on Gimv’s last published equity value at 30 June 2013. Over the entire investment period, the shareholding’s return is above Gimv’s historic average. No further financial details on this transaction will be disclosed.
